/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Adjuvant Therapy is an emerging landscape with 20 programs across 12 companies. The most active players are Nanjing Sanhome Pharmaceutical, Co., Ltd.. 11 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Bubble size = clinical trials
Key Players
Pipeline
Analysis
70%
Small molecule
14 of 20 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
61
clinical trials
Clinical Trials
61 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)